...
首页> 外文期刊>The journal of immunology >Induction of Permanent Mixed Chimerism and Skin Allograft Tolerance Across Fully MHC-Mismatched Barriers by the Additional Myelosuppressive Treatments in Mice Primed with Allogeneic Spleen Cells Followed by Cyclophosphamide
【24h】

Induction of Permanent Mixed Chimerism and Skin Allograft Tolerance Across Fully MHC-Mismatched Barriers by the Additional Myelosuppressive Treatments in Mice Primed with Allogeneic Spleen Cells Followed by Cyclophosphamide

机译:额外的骨髓抑制治疗由同种异体脾细胞引发的小鼠继发环磷酰胺诱导的完全混合MHC不匹配障碍的永久混合嵌合体和皮肤同种异体移植耐受性

获取原文

摘要

A pure method of drug (cyclophosphamide plus busulfan)-induced skin allograft tolerance in mice that can regularly overcome fully H-2-mismatched barriers in mice has been established. The components of the method are i.v. administration of 1 × 108 allogeneic spleen cells on day 0, i.p. injection of 200 mg/kg CP and 25 mg/kg busulfan on day 2, and i.v. injection of T cell-depleted 1 × 107 bone marrow cells from the same donor on day 3. Recipient B10 (H-2b; IE?) mice prepared with this conditioning developed donor-specific tolerance, and long-lasting survival of skin allografts was shown in almost of the recipient mice. In the tolerant B10 mice prepared with new conditioning, stable multilineage mixed chimerism was observed permanently, and IE-reactive Vβ11+ T cells were reduced in periphery as seen in untreated B10.D2 (H-2d; IE+) mice. The specific tolerant state was confirmed by the specific abrogation against donor Ag in the assays of CTL activity and MLR and donor-specific acceptance in the second skin grafting. These results demonstrated that the limitation of standard protocol of cyclophosphamide-induced tolerance, which have been reported by us since 1984, can be overcome by the additional treatments with the myelosuppressive drug busulfan, followed by 1 × 107 T cell-depleted bone marrow cells. To our knowledge, this is the first report to induce allograft tolerance with a short course of the Ag plus immunosuppressive drug treatment without any kind of mAbs (pure drug-induced tolerance).
机译:建立了一种药物(环磷酰胺加环丁砜)诱导的小鼠皮肤同种异体移植耐受性的纯方法,该方法可以定期克服小鼠中完全与H-2不匹配的障碍。该方法的组成部分是i.v.在第0天,腹膜内注射1×108个同种异体脾细胞。第2天注射200 mg / kg CP和25 mg / kg busulfan。在第3天,从同一供体注射了贫T细胞的1×107骨髓细胞。用这种条件制备的收件人B10(H-2b; IE?)小鼠表现出了供体特异性耐受性,同种异体皮肤的持久存活率很高。在几乎所有的受体小鼠中都可见。在用新的条件制备的耐受性B10小鼠中,永久观察到稳定的多谱系混合嵌合体,与未处理的B10.D2(H-2d; IE +)小鼠相比,IE反应性Vβ11+ T细胞的外周减少。通过在第二次植皮中的CTL活性和MLR分析以及供体特异性接受的检测中针对供体Ag的特异性废除来确认特定的耐受状态。这些结果表明,自1984年以来我们就已经报道了环磷酰胺诱导的耐受性标准方案的局限性,可以通过用骨髓抑制药物白消安随后用1×107 T细胞耗尽的骨髓细胞进行其他治疗来克服。据我们所知,这是第一个在短疗程的Ag加免疫抑制药物治疗下诱导同种异体移植耐受性的报道,无任何类型的mAb(纯药物诱导的耐受性)。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号